Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 dose-finding placebo-controlled phase 2 trial in active rheumatoid arthritis on stable methotrexate
2006-001550-27Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canakinumab in rheumatoid arthritis (RA) (4 arms), sponsored by Novartis. Primary endpoint: ACR50 response at 12 weeks. Started Jun 2006; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-001550-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001550-27.